Charles River Laboratories Intl. Inc vs First Solar, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while First Solar, Inc. trades at $177.82 (market cap $19.22B). The key difference: First Solar, Inc. is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and First Solar, Inc. for 76 Days on average.
| CRL | FSLR | |
|---|---|---|
Market Cap | $14.23B | $19.22B |
Volume | 1,176,885 | 2,067,793 |
Sector | Health | Energy |
52-Week High | $310.77 | $318.30 |
52-Week Low | $149.93 | $172.11 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $17.06B | $17.69B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
First Solar (FSLR) trades at $178.85, down 0.71% on the day, with a bearish technical signal and key support at $175. Fundamentally, the company shows strong profitability with a 32.47% net income margin and robust revenue growth, though it recently missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit filing and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
The outlook balances solid fundamentals against near-term headwinds. Analyst consensus is bullish with a $267.59 price target, but risks include solar industry volatility, interest rate sensitivity, and competitive challenges. Earnings growth and execution on guidance are critical for stock performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →